Knopp Receives FDA Fast Track Designation for ALS Drug

Knopp Neurosciences Inc. announced that it received Fast Track designation from the FDA for the development of KNS-760704 for ALS. Knopp completed the randomized, placebo-controlled portion of its Phase 2 studies of KNS-760704 in 102 ALS patients and expects to initiate Phase 3 studies in the U.S. and Europe in 2010. The Fast Track Program was created to facilitate the development and expedite the review of new drugs with the potential to meet unmet needs in serious or life-threatening conditions.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail